iBio, Inc. Files 8-K with Financial Updates

Ticker: IBIO · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1420720

Ibio, Inc. 8-K Filing Summary
FieldDetail
CompanyIbio, Inc. (IBIO)
Form Type8-K
Filed DateAug 18, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $8.8 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, corporate-update

TL;DR

iBio dropped an 8-K on Aug 18th - check financials and operations.

AI Summary

On August 18, 2025, iBio, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and financial condition, as well as other events and financial statements. The report was filed from their principal executive offices in San Diego, California.

Why It Matters

This 8-K filing provides investors with crucial updates on iBio, Inc.'s financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain a wide range of information, from routine updates to significant corporate events, requiring careful analysis to assess risk.

Key Players & Entities

  • iBio, Inc. (company) — Registrant
  • August 18, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 001-35023 (identifier) — Commission File Number
  • 262797813 (identifier) — IRS Employer Identification No.
  • San Diego, California (location) — Address of principal executive offices
  • iBioPharma, Inc. (company) — Former company name
  • InB:Biotechnologies, Inc. (company) — Former company name

FAQ

What specific financial results or operational events are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and 'Other Events', but specific details are not provided in the provided text.

When was the earliest event reported in this filing?

The earliest event reported was on August 18, 2025.

What is iBio, Inc.'s principal executive office address?

The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

What were iBio, Inc.'s former company names?

The company was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.

What is the SIC code for iBio, Inc.?

The Standard Industrial Classification code for iBio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,432 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2025-08-18 16:24:08

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq S
  • $8.8 million — cash equivalents and restricted cash of $8.8 million as of June 30, 2025. The preliminary f

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. On a preliminary unaudited basis, iBio, Inc., a Delaware company (the "Company," "we" or "our") expects to report that it had cash, cash equivalents and restricted cash of $8.8 million as of June 30, 2025. The preliminary financial results above are the Company's preliminary estimates based on currently available information and are subject to completion of the Company's financial closing procedures. They do not present all necessary information for an understanding of the Company's financial condition as of June 30, 2025. The Company's independent registered public accounting firm has not conducted an audit or review of and does not express an opinion or any other form of assurance with respect to, the preliminary unaudited results. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the preliminary estimates set forth above. We expect to complete our audited financial statements for the year ended June 30, 2025 later this quarter . Accordingly, undue reliance should not be placed on the preliminary estimates.

01. Other Events

Item 8.01. Other Events. Corporate Presentation On August 18, 2025, the Company posted an updated corporate presentation on its website (the "Presentation") for use in meetings with investors, analysts and others, which discusses the development of its obesity and cardiometabolic diseases pipeline. The Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Business Description The Company has updated its business description as set forth below: Overview We are a preclinical stage biotechnology company leveraging the power of Artificial Intelligence ("AI") for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning ("ML") to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed to address unmet needs by current GLP-1 receptor agonists. We believe the future of obesity care lies not just in weight loss—but in quality weight loss. Current interventional therapies such as GLP-1 receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability. We are developing second-generation therapies to meet these unmet needs, using the power of AI-guided antibody design and advanced screening technologies. Our obesity strategy is built on three key principles. First, we aim to develop next-generation antibody therapeutics addressing limitations of current approved treatments, offering options with a goal to preserve muscle mass, target fat selectively, and provide durable weight loss with improved tolerability. Second, we are focusing on targets with strong human validation, which we believe both helps reduce development risk and increase the likelihood of clinical success. Lastly,

Risk Factors

Risk Factors The Company has updated certain of its risk factors. The risk factors listed below should be read in conjunction with the risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2024 and its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024 and March 31, 2025. Our most advanced product candidates depend on intellectual property licensed from third parties and termination of any of these or future licenses could result in the loss of significant rights, which could adversely affect our business, results of operations and financial condition. We are dependent on patents, know-how and proprietary technology, some of which is owned and some of which is licensed from others. With respect to our obesity and cardiometabolic program, we have a license to four provisional applications for a future U.S. patent application that relate to our leading anti-myostatin antibody product candidate, IBIO-600, alone and when used in combination with Activin A. In addition, we have a license to three provisional applications for a future U.S. patent application that relate to our Activin E engineered antibody candidate, IBIO-610. These licenses exist under two exclusive license agreements (the "AstralBio Licenses") with AstralBio granting us exclusive, worldwide licenses to develop, manufacture, commercialize and otherwise exploit, IBIO-600 and IBIO-610, which are our most advanced preclinical product candidates. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. The AstralBio Licenses impose, and we expect that future license and acquisition agreements will impose, various diligence, milestone payments and other obligations on us. If we fail to comply with our obligations under current or future intellectual property license agreements, we may be required to pay damages and the licensor may h

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.